• Loading stock data…

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

Last Updated on November 2, 2022 by GlobeNewsWire

– Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) –

– Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists (ASRS) 2022 Annual Meeting and American Academy of Ophthalmology (AAO) 2022 Annual Meeting –

– Net product revenue of $9.7 million in Q3 2022; a 13% increase from Q3 2021 –

Management to host a conference call and webcast today at 8:30 a.m. ET –

WATERTOWN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate developments.

“In the third quarter, we continued to execute on key catalysts across our clinical-stage pipeline with the initiation of two Phase 2 clinical trials studying EYP-1901 in wet AMD and NPDR, following our encouraging positive safety and efficacy Phase 1 data,” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. “There is a great unmet need in wet AMD and NPDR for convenient, safe and efficacious long-acting treatment options that maintain the patient’s existing vision proactively. Bolstered by our strong balance sheet, we are well-positioned to advance EYP-1901 through these trials and explore its potential to significantly improve the lives of patients living with these serious eye disorders.”

Ms. Lurker continued, “Our commercial team delivered a strong quarter with $9.7 million in net product revenue, driven by strong customer demand for YUTIQ(R) by retinal specialists.”

R&D Highlights and Updates

The first patient was dosed in the Phase 2 PAVIA clinical trial of EYP-1901 for the treatment of NPDR in September 2022. This twelve-month, randomized, controlled trial is expected to enroll approximately 105 patients randomly assigned to one of two doses of EYP-1901 (approximately 2 mg or 3 mg), or to the control group receiving a sham injection. More information about the study is available at clinicaltrials.gov (identifier: NCT05383209).The first patient was dosed in the Phase 2 DAVIO 2 clinical trial of EYP-1901 for the treatment of wet AMD in July 2022. This twelve-month, randomized, controlled trial is expected to enroll approximately 150 patients previously treated with a standard-of-care anti-VEGF therapy, randomly assigned to one of two doses of EYP-1901 (approximately 2 mg or 3 mg) or an aflibercept control. Topline data is expected in the fourth quarter of 2023. More information about the study is available at clinicaltrials.gov (identifier: NCT05381948).The Company will be presenting data at the Retina Society 55th Annual Scientific Meeting in November 2022. Sunil Patel, M.D., Ph.D. will present an encore oral presentation of the EYP-1901 final twelve-month Phase 1 DAVIO results with an additional subset analysis of patients with no excess fluid at screening. Also, data from the YUTIQ(R) CALM registry study will be presented as a poster presentation by Pouya Dayani, M.D. titled “CALM: Retrospective Registry Study to Collect Real-World Data On the Fluocinolone Acetonide Intravitreal Implant 0.18 Mg For the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment – Year 1 Update”. The CALM study is a Phase 4, multi-center registry study and a collaboration between EyePoint and the Cleveland Clinic.Final twelve-month data from the Phase 1 DAVIO clinical trial of EYP-1901 for wet AMD was presented at the AAO 2022 Annual Meeting in September 2022 and topline data was presented at the ASRS 2022 Annual Meeting in July 2022. The data reinforced a positive safety and efficacy profile for EYP-1901 and showed no dose limiting toxicities, no reports of ocular serious adverse events (SAEs) and no drug-related systemic SAEs. There were no reported events of vitreous floaters, endophthalmitis, retinal detachment, implant migration in the anterior chamber, retinal vasculitis, or posterior segment inflammation. The data also confirmed stable best corrected visual acuity (BCVA) (-4.12 ETDRS letters), stable central subfield thickness (CST) on optical coherence tomography (OCT) (-2.76 ?m), and a clinically significant 73% reduction in treatment burden (75% at six-months).

Recent Corporate Highlights

In October 2022, the Company and ImprimisRx mutually terminated an agreement for the commercialization of DEXYCU effective December 31, 2022. This is a result of the proposed “Medicare Hospital Outpatient Prospective Payment System and ASC Payment System Proposed Rule” published in the Federal Register by the Center for Medicare & Medicaid Services (CMS) on July 26, 2022, not containing an extension of the pass-through payment period for DEXYCU(R) beyond December 31, 2022. The final rule was published on November 1, 2022, confirming that CMS will not extend pass-through reimbursement status for DEXYCU beyond December 31, 2022.Karen Zaderej was appointed to the Company’s Board of Directors in July 2022. Ms. Zaderej brings more than 35 years of biopharmaceutical and medical device experience to the board, and currently serves as the President and CEO of AxoGen.

Commercial Performance in Third Quarter 2022

Net product revenue for YUTIQ and DEXYCU was $7.3 million and $2.4 million, respectively.

Customer demand for YUTIQ and DEXYCU was approximately 890 units and 14,100 units, respectively.

Review of Results for the Third Quarter ended September 30, 2022

For the third quarter ended September 30, 2022, total net revenue was $10.0 million compared to $9.1 million for the quarter ended September 30, 2021. Net product revenue for the third quarter was $9.7 million, compared to net product revenues for the third quarter ended September 30, 2021 of $8.6 million.

Net revenue from royalties and collaborations for the third quarter ended September 30, 2022 totaled $0.3 million compared to $0.5 million in the corresponding period in 2021.

Operating expenses for the third quarter ended September 30, 2022 totaled $28.4 million versus $24.4 million in the prior year period, primarily driven by investment in personnel across the organization, including non-cash stock compensation, and ongoing clinical trial and development costs for EYP-1901. Non-operating expense, net, totaled $0.02 million and net loss was $18.4 million, or ($.49) per share, compared to a net loss of $16.7 million, or ($0.58) per share, for the prior year period.

Cash and investments at September 30, 2022 totaled $157.3 million compared to $171.2 million at June 30, 2022.

Financial OutlookWe expect the cash, cash equivalents and investments on hand on September 30, 2022 and expected net cash inflows from our product sales will enable us to fund our current and planned operations into the second half of 2024.

Conference Call InformationEyePoint will host a conference call today, at 8:30 a.m. ET to discuss the results for the third quarter ended September 30, 2022 and recent corporate developments. To access the live conference call, please register at https://register.vevent.com/register/BIc813a58533cb4c0191e12c73ab3f1232. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert(R) technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients’ eyes across four U.S. FDA approved products, including YUTIQ(R) for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration and non-proliferative diabetic retinopathy; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the success of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of our commercialized products, YUTIQ(R) and DEXYCU(R); the loss of pass-through reimbursement status for DEXYCU at the end of 2022; market acceptance of our products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy and the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investors:

Christina TartagliaStern IRDirect: 212-698-8700christina.tartaglia@sternir.com

Media Contact:

Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)(In thousands, except per share data) Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2022 2021 2022 2021 Revenues: Product sales, net $9,720 $8,587 $30,048 $24,127 License and collaboration agreements 52 159 160 594 Royalty income 240 313 663 674 Total revenues 10,012 9,059 30,871 25,395 Operating expenses: Cost of sales, excluding amortization of acquired intangible assets 1,405 1,825 4,916 5,144 Research and development 11,162 8,498 34,099 19,582 Sales and marketing 6,016 7,374 19,592 19,692 General and administrative 9,212 6,060 26,321 16,358 Amortization of acquired intangible assets 615 615 1,845 1,845 Total operating expenses 28,410 24,372 86,773 62,621 Loss from operations (18,398) (15,313) (55,902) (37,226) Other income (expense): Interest and other income, net 640 6 1,067 286 Interest expense (662) (1,388) (2,408) (4,110) Gain (loss) on extinguishment of debt – — (1,559) 2,065 Total other expense, net (22) (1,382) (2,900) (1,759) Net loss $(18,420) $(16,695) $(58,802) $(38,985) Net loss per common share – basic and diluted $(0.49) $(0.58) $(1.58) $(1.42) Weighted average common shares outstanding – basic and diluted 37,338 28,766 37,305 27,429

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)(In thousands) September 30, December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $75,362 $178,593 Marketable securities 81,897 32,965 Accounts and other receivables, net 20,876 18,354 Prepaid expenses and other current assets 10,436 4,217 Inventory 3,531 3,616 Total current assets 192,102 237,745 Operating lease right-of-use assets 6,319 2,252 Intangible assets, net 20,904 22,749 Other assets 1,165 626 Total assets $220,490 $263,372 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses $22,116 $21,807 Deferred revenue 1,169 1,069 Short-term borrowings 10,475 – Other current liabilities 496 782 Total current liabilities 34,256 23,658 Long-term debt 29,251 36,562 Deferred revenue – noncurrent 13,798 14,560 Operating lease liabilities – noncurrent 6,235 1,860 Other long-term liabilities 600 2,352 Total liabilities 84,140 78,992 Stockholders’ equity: Capital 763,596 752,636 Accumulated deficit (627,899) (569,097)Accumulated other comprehensive income 653 841 Total stockholders’ equity 136,350 184,380 Total liabilities and stockholders’ equity $220,490 $263,372




Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: